CEPI

Advancing the development of Chikungunya vaccine and contributing to expand access to vulnerable populations in endemic countries

Gillian Mason
Access & Business Development, CEPI

Access objectives are often framed against these components of equitable access



Sensitivity: Official Use

Key updates on activities that will support equitable access

- A first Chikungunya vaccine is now approved for adults
- Good progress towards expanding the label to 12-year-olds and older
- Further expansion being made possible through studies in pregnant women and paediatrics

- Approvals by USA, Europe, Canada, MHRA (UK) in Feb 2025
- ANVISA (Brazil) approval expected imminently (VLA1553 (IXCHIQ))
- WHO PQ submission expected at the end of 2025 (VLA1555)
- The Instituto Butantan (IB) vaccine will be submitted for WHO PQ post ANVISA licensure

- VLA-Instituto Butantan (IB) Tech Transfer agreement 2021 to support affordable supply in Latin America
- VLA-Serum Institute of India (SII) Tech Transfer agreement 2025 to support affordable supply in Asia

Sensitivity: Official Use

Utilization of the CEPI-funded licensed vaccine stockpile

- Valneva managed inventory stockpile of up to 200,000 doses for 18 yrs and above.
- CEPI option to replenish that stockpile once utilized/expired
- Valneva committed to CEPI's equitable access policy and affordable supply of these vaccines in LMICs. Commitment flows down to Instituto Butantan (IB), responsible for supply to LMICs once IB product is licensed
- Valneva, Instituto Butantan, and CEPI are in discussions regarding how to operationalize this
- CEPI have been in discussion with various multi-lateral organisations regarding how to allocate and implement these stockpiles, however understanding the current geopolitical and funding situation, uncertainties mean finding solutions may take longer than expected

Sensitivity: Official Use

O'NEILL REVIEW OF CEPI CHIKUNGUNYA PARTNERSHIP AGREEMENTS SUPPORTS TRANSPARENCY

SCOPE

An Equitable Access (EA) review of CEPI's Chikungunya vaccine development agreements commissioned in 2024. The findings of the review to be published to the wider public (2Q25)

4 funding agreements, secondary literature, interviews

Commitment to EA

How EA was incorporated into CEPI's partnerships leading to the licensure of the first Chikungunya vaccine in 2023 and other candidates now in late-stage development

Measuring Performance

Evaluate and generate lessons learned on how CEPI performed against its commitment to equitable access

Learnings for the future

Learnings and how they can contribute to future CEPI's agreements and activities

CEPI

O'NEILL INSTITUTE FOR NATIONAL & GLOBAL HEALTH LAW GEORGETOWN LAW

Sensitivity: Official Use

Further EA areas to explore

We collectively need to continue to:

- Support evidence generation and regulatory approvals in LMICs in regions affected by Chikungunya
- Work with the SAGE Working group to understand policy evidence generation needs
- Explore evidence generation during outbreaks, including the viability of using a stockpile to conduct operational research whilst deploying stockpile vaccines
- Understand the epidemiology of the disease and future demand for Chikungunya vaccines
- Align with partners to discuss financing and procurement of vaccines to support activities that are further downstream of the vaccine value chain

Sensitivity: Official Use